Last verified: April 25, 2026 — including the April 21, 2026 Bridge extension through December 31, 2027 and the April 6, 2026 addition of Foundayo to the eligible drug list.

How to Qualify for Medicare GLP-1 Bridge Program in 2026–2027

By The RX Index TeamUpdated April 25, 2026Editorial StandardsMethodology

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

The bottom line

Qualifying comes down to three things you have to clear at the same time: an eligible Medicare Part D drug plan, a prescription for a Bridge-covered medication used specifically for weight reduction, and a doctor willing to attest that you meet one of three CMS clinical routes:

•BMI ≥ 35 at the time you started GLP-1 therapy (no other diagnosis required), or
•BMI ≥ 30 with HFpEF, uncontrolled hypertension despite two antihypertensive medications, or chronic kidney disease Stage 3a or above, or
•BMI ≥ 27 with prediabetes (per ADA guidelines), prior heart attack, prior stroke, or symptomatic peripheral artery disease.

If you clear all three, you pay $50 per month for Wegovy, Zepbound KwikPen, or Foundayo at any pharmacy from July 1, 2026 through December 31, 2027 (extended April 21, 2026 — most pages haven’t caught up).

The part most articles bury: That $50 doesn’t count toward your Part D out-of-pocket cap, Extra Help can’t reduce it, and manufacturer coupons can’t stack on top. For most readers it’s still a massive savings. For some, it’s not the slam dunk the headlines suggest. We’ll show you exactly how to tell which group you’re in.

Quick check: where do you fit?

Your situation	Likely path
BMI ≥ 35 when you started (or are starting) GLP-1 therapy + eligible Part D	✅ Likely qualifies — Tier 1
BMI ≥ 30 + HFpEF, uncontrolled hypertension on 2 meds, or CKD Stage 3a+	✅ Likely qualifies — Tier 2
BMI ≥ 27 + prediabetes, prior heart attack, prior stroke, or symptomatic PAD	✅ Likely qualifies — Tier 3
Original Medicare with no Part D	❌ Not enough — enroll in Part D first
Wegovy or Zepbound prescribed for cardiovascular risk reduction or sleep apnea	⚠️ Use regular Part D, not the Bridge
Ozempic, Mounjaro, or Rybelsus	❌ Not Bridge-covered — may be covered by Part D for type 2 diabetes
Zepbound vial or single-dose pen	❌ Not Bridge-covered — KwikPen only
Compounded semaglutide or tirzepatide	❌ Not Bridge-covered (FDA-approved drugs only)

Check my Bridge eligibility — personalized answer in 60 seconds →

Free. No email required. Outputs a prescriber checklist with your tier and CMS attestation language.

What we verified for this page

✅Eligibility tiers and prior authorization criteria — directly from the CMS Medicare GLP-1 Bridge FAQ

✅Eligible drugs and formulations — including the April 6, 2026 Foundayo addition and the Zepbound KwikPen-only clarification

✅Program dates — including the April 21, 2026 extension through December 31, 2027

✅Plan-type eligibility — verified against the full CMS plan-type list

✅Pharmacy claims routing — BIN 028918, PCN MEDDGLP1BR, processor SS&C Health, routed through RelayHealth, effective July 1, 2026 (CMS payer sheet dated March 16, 2026)

✅Cost limitations (LIS exclusion, $2,100 OOP cap, no coupon stacking) — cross-verified with KFF policy analysis

How to qualify for Medicare GLP-1 Bridge program: the 4 gates

To qualify, you have to clear four gates at the same time. Miss any single gate and you’re out of the Bridge — but each failed gate points to a different next-best path.

$How to qualify for Medicare GLP-1 Bridge — 4 gates infographic: Gate 1 eligible Medicare drug coverage (standalone Part D PDP, Medicare Advantage MA-PD, Special Needs Plan, Employer/Union EGWP, or LI NET — not Original Medicare without Part D, not PFFS, not PACE); Gate 2 weight-reduction prescription for weight reduction and weight maintenance only; Gate 3 meet 1 of 3 clinical routes (BMI 35 or higher; BMI 30 or higher with heart failure preserved ejection fraction, uncontrolled hypertension on 2 blood-pressure medications, or CKD stage 3a+; BMI 27 or higher with prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease); Gate 4 covered medication (Wegovy injection or tablets, Zepbound KwikPen only, or Foundayo). Not covered: Ozempic/Mounjaro/Rybelsus, compounded GLP-1 drugs, Zepbound vial or single-dose pen, Original Medicare without Part D. Benefit: $50 flat copay, outside Part D, Extra Help and coupons do not apply.$

Gate 1 — Coverage

Are you in a Medicare plan that includes Part D-style drug coverage? Original Medicare with a Medigap plan but no Part D doesn't count. We list every plan type below.

Gate 2 — Use case

Is the prescription specifically for weight reduction and weight maintenance? If your doctor is writing the script for diabetes, sleep apnea, or cardiovascular risk reduction, you go through your regular Part D plan — not the Bridge — even if the drug is the same.

Gate 3 — Clinical route

Do you fit one of the three BMI/condition tiers CMS published? Tier 1 is BMI ≥ 35 alone. Tier 2 is BMI ≥ 30 plus HFpEF, uncontrolled hypertension on 2+ meds, or CKD Stage 3a+. Tier 3 is BMI ≥ 27 plus prediabetes, prior MI, prior stroke, or symptomatic PAD.

Gate 4 — Drug and formulation

Is the prescription for Wegovy injection or tablets, Zepbound KwikPen, or Foundayo? The Zepbound vial and single-dose pen aren't Bridge-eligible. Ozempic, Mounjaro, Rybelsus, and any compounded GLP-1 aren't either.

The Bridge doesn’t open until July 1, 2026, but the prep work starts now. We’ll walk you through it step by step below. Also see our companion Medicare GLP-1 Bridge eligibility deep dive for the full CMS rule analysis.

Check my eligibility route — 60 seconds, free, no email required →

Free. No email required. Outputs a prescriber checklist with your tier and CMS attestation language.

The 3 BMI and condition routes — pick the one you fit

CMS uses three eligibility tiers and you only need to meet one. Critically, BMI is measured at the time you initiated therapy — not necessarily today.

The full eligibility matrix (with the mistakes other pages make)

Tier	BMI requirement	Required additional diagnosis	Common mistake other pages make
Tier 1	≥ 35 at therapy initiation	None — BMI alone qualifies you	Saying "obesity" alone qualifies regardless of BMI number
Tier 2	≥ 30 at therapy initiation	One of: HFpEF; uncontrolled hypertension (SBP > 140 or DBP > 90 while on two antihypertensive medications); CKD Stage 3a or above	Saying BMI ≥ 30 alone qualifies, or treating any high blood pressure as qualifying
Tier 3	≥ 27 at therapy initiation	One of: prediabetes per ADA guidelines; prior myocardial infarction; prior stroke; symptomatic peripheral artery disease	Treating sleep apnea or general cardiovascular disease as qualifying — those are Part D indications, not Bridge

Source: CMS Medicare GLP-1 Bridge FAQ, verified April 25, 2026.

One quirk worth knowing: BMI is measured at therapy initiation

If you started Wegovy through a cash-pay program in 2024 with a BMI of 37 and now your BMI is down to 33, your prescriber attests to the BMI you had when you started — not your current number. CMS specifically clarifies this. Losing weight on the medication doesn’t disqualify you from continuing it under the Bridge. Some patients have been on a GLP-1 for over a year and assume they don’t qualify because they’ve already shed twenty pounds. Read the criteria carefully — you probably still qualify.

What “lifestyle modification” actually means in the attestation

CMS requires the prescription to be written in combination with current and ongoing lifestyle modification including structured nutrition and physical activity consistent with the applicable FDA approved label. CMS does not specify a paid program, registered nutritionist, or gym membership — it requires current and ongoing lifestyle modification documented alongside the medication. If your doctor isn’t comfortable attesting to that language, ask them to document the diet and exercise conversation in your visit notes.

Prediabetes per ADA guidelines — the actual numbers

If you’re qualifying via Tier 3 with prediabetes, ADA defines prediabetes by any one of these lab values:

•A1C 5.7%–6.4%
•Fasting plasma glucose 100–125 mg/dL
•2-hour plasma glucose 140–199 mg/dL during a 75g oral glucose tolerance test

Source: American Diabetes Association. Your prescriber will look for one of these in your chart — pull recent labs before your visit.

BMI quick reference by height

Height	BMI 27 (Tier 3 entry)	BMI 30 (Tier 2 entry)	BMI 35 (Tier 1 entry)
5′2″	~148 lbs	~164 lbs	~191 lbs
5′4″	~157 lbs	~174 lbs	~204 lbs
5′6″	~167 lbs	~186 lbs	~217 lbs
5′8″	~177 lbs	~197 lbs	~230 lbs
5′10″	~188 lbs	~209 lbs	~244 lbs
6′0″	~199 lbs	~221 lbs	~258 lbs

Estimates only. Your actual BMI must be measured by your provider for the attestation.

Get my printable Doctor Visit Kit — free, no email, includes your tier and CMS attestation language →

Free. No email required. Outputs a prescriber checklist with your tier and CMS attestation language.

Which Medicare plans qualify (and which don’t)

You qualify if you’re enrolled in a standalone Part D PDP, a Medicare Advantage plan that includes drug coverage (MA-PD), a Special Needs Plan, an Employer Group Waiver Plan, or LI NET. Original Medicare without a Part D plan, PFFS, Section 1876 cost contracts, PACE organizations, and fallback plans are not eligible (unless you’re also enrolled in a standalone PDP).

Your plan type	Bridge eligible?	Notes
Standalone Part D PDP	✅ Yes	The most common eligible plan type
Medicare Advantage with drug coverage (MA-PD)	✅ Yes	HMO, HMO-POS, Local PPO, Regional PPO
Special Needs Plans (SNPs)	✅ Yes	All eligible SNP types
Employer/Union Group Waiver Plans (EGWPs)	✅ Yes	Eligible
Limited Income Newly Eligible Transition (LI NET)	✅ Yes	Eligible (LI NET infrastructure also runs the Bridge central processor)
Dually eligible (Medicare + Medicaid)	✅ Yes	If enrolled in an eligible Part D plan type
Original Medicare with no Part D	❌ No	Must enroll in Part D first
Original Medicare with Medigap only	❌ No	Medigap doesn't include drug coverage
Private Fee-for-Service (PFFS)	❌ No	Unless also enrolled in a standalone PDP
Section 1876 cost contracts	❌ No	Unless also enrolled in a standalone PDP
Section 1833 health care prepayment plans	❌ No	Unless also enrolled in a standalone PDP
PACE organizations	❌ No	Not eligible
Fallback plans	❌ No	Not eligible
Religious fraternal benefit plans	❌ No	Unless also enrolled in a standalone PDP

Source: CMS Medicare GLP-1 Bridge FAQ.

Not sure what plan type you have?

Look at your insurance card — it’ll usually say “Part D” or “MA-PD.” Or sign in at Medicare.gov and look at your enrollment summary, or call 1-800-MEDICARE (1-800-633-4227). If you’re on Original Medicare without Part D, Annual Enrollment runs October 15–December 7 each year, or you may qualify for a Special Enrollment Period. Don’t make that decision based on the Bridge alone — a Part D plan affects every prescription you take, not just the GLP-1.

Which drugs and formulations the Bridge actually covers

Three FDA-approved GLP-1 medications are eligible: Wegovy (injection and tablets, all CMS-listed formulations), Zepbound KwikPen only (the single-dose vial and single-dose pen are excluded), and Foundayo (orforglipron, added April 6, 2026). The drug must be prescribed specifically for weight reduction and weight maintenance.

The eligible drug list, as of April 25, 2026

Drug	Active ingredient	Form	Bridge eligible?
Wegovy®	Semaglutide	Injection (all CMS-listed formulations)	✅ Yes
Wegovy® tablets	Semaglutide	Tablets (all CMS-listed formulations)	✅ Yes
Zepbound® KwikPen	Tirzepatide	Multi-dose KwikPen	✅ Yes — KwikPen only
Zepbound® single-dose vial	Tirzepatide	Vial	❌ No
Zepbound® single-dose pen	Tirzepatide	Single-use pen	❌ No
Foundayo® (orforglipron)	Orforglipron	Tablet	✅ Yes — Added April 6, 2026
Ozempic®	Semaglutide	Injection	❌ No — May be covered by Part D for type 2 diabetes
Mounjaro®	Tirzepatide	Injection	❌ No — May be covered by Part D for type 2 diabetes
Rybelsus®	Semaglutide	Tablet	❌ No — May be covered by Part D for type 2 diabetes
Saxenda® (liraglutide)	Liraglutide	Injection	❌ No
Compounded semaglutide / tirzepatide	—	Any	❌ No — Bridge covers FDA-approved drugs only; compounds not allowed per CMS payer sheet

The Zepbound KwikPen-only rule

On April 6, 2026, CMS clarified that only the Zepbound KwikPen is included. If your doctor writes a prescription for the Zepbound single-dose vial or single-dose pen, the Bridge won’t cover it. When you ask for Zepbound, ask specifically for the KwikPen. This is the kind of detail that can derail a pharmacy run if you don’t catch it ahead of time.

Two oral options, not one

Foundayo gets the headlines as the newest oral GLP-1, but Wegovy tablets are also Bridge-covered for weight loss. If you can’t tolerate weekly injections, ask your clinician whether Foundayo or Wegovy tablets is the right fit — they’re different molecules with different dosing patterns.

The “weight loss only” rule, plainly stated

The Bridge covers GLP-1 medications only when prescribed for weight reduction and weight maintenance. If you have type 2 diabetes, your Ozempic/Mounjaro/Rybelsus goes through your normal Part D plan. Wegovy for cardiovascular risk reduction goes through Part D. Zepbound for obstructive sleep apnea goes through Part D. CMS monitors plans to ensure they don’t shift existing Part D-covered prescriptions to the Bridge.

What it actually costs (and the part most pages skip)

Your monthly copay is $50 flat for any Bridge-covered medication. But the $50 you pay does not count toward your Part D deductible or your $2,100 annual out-of-pocket cap, the Low-Income Subsidy (“Extra Help”) cannot be applied to Bridge claims, and manufacturer savings cards cannot be stacked.

Question	Answer
Your monthly copay	$50 flat
Manufacturer net price	$245 per monthly supply
Total beneficiary cost over 18 months (July 2026 – December 2027)	$900 if filled monthly
Counts toward Part D deductible?	No
Counts toward $2,100 Part D OOP cap?	No
Low-Income Subsidy ('Extra Help') applies?	No
Manufacturer coupons / discount programs apply?	No — cannot be applied to Bridge claims
Paper claims or direct member reimbursement?	No — electronic claims only
Pharmacy must opt in?	No — pharmacies do not need to opt in

The honest math (and the one admission we owe you)

If you’re a low-income Medicare beneficiary on Extra Help — where in 2026 most enrollees pay no more than $5.10 for generics and $12.65 for brand-name drugs — the Bridge still charges you $50/month. Because the Bridge sits outside the Part D benefit, LIS subsidies that reduce your other drug costs don’t apply here. Across 18 months, that’s $900 that won’t help you reach any Part D cap.

For the right reader: Wegovy and Zepbound list at well over $1,000/month retail. The Bridge is a fraction of that. If your alternative is paying cash, $50/month is a different financial universe.

For the wrong reader: If you’re on LIS with significant other prescription spending, your $50 Bridge copay is real money that doesn’t help you reach your OOP cap. Your local SHIP counselor can do this analysis with you for free — find them at shiphelp.org.

The 6-step path to coverage — start now, don’t wait until July

The Bridge launches July 1, 2026, but most prep takes weeks. Starting in April or May puts you in front of the rush.

How to get Medicare GLP-1 Bridge coverage — 6-step path: Step 1 Confirm your plan (make sure you have eligible Medicare drug coverage: Part D, MA-PD, SNP, EGWP, or LI NET). Step 2 Gather your records (bring your current BMI, your starting BMI if you already began GLP-1 therapy, and records for any qualifying condition). Step 3 Book a prescribing visit (ask your clinician to review Bridge eligibility for weight reduction and weight maintenance). Step 4 Use a covered drug (Wegovy injection or tablets, Zepbound KwikPen only, or Foundayo). Step 5 Send the prior authorization to the right place (PA goes to the CMS central processor — not to your Part D plan). Step 6 Fill the prescription (at the pharmacy the Bridge copay is $50 per month). Important rules: Bridge claims are outside Part D; the $50 copay does not count toward your Part D out-of-pocket cap; Extra Help does not reduce the $50 copay; manufacturer coupons do not apply. Use regular Part D instead if prescribed for: type 2 diabetes, Wegovy for cardiovascular risk reduction, Zepbound for obstructive sleep apnea.

1
Confirm your Medicare plan qualifies (now)
Use the plan-type matrix above. If unsure, call 1-800-MEDICARE. Original Medicare without Part D doesn't qualify.
2
Document your BMI and qualifying conditions (now through May)
Schedule a routine PCP visit. Get your BMI measured. If your BMI was higher when you started GLP-1 therapy, gather records showing the higher number. Pull labs and notes: A1C for prediabetes, eGFR for CKD staging, blood pressure logs and medication list for uncontrolled hypertension, cardiology records for prior MI/stroke/PAD, echocardiogram summary for HFpEF.
3
Schedule your prescribing visit (May–June 2026)
Many primary care practices are running multi-week waits. Don't wait until July 1. Tell the scheduler the visit is for 'weight management.'
4
Bring your Doctor Visit Kit (May–June 2026)
The kit includes the exact CMS attestation language, your tier, the documentation list, and the routing instruction so your doctor sends the PA to the right place.
5
Confirm where the prior auth is being submitted
It must go to the CMS central processor (Humana / LI NET, via SS&C Health and RelayHealth) — not to your Part D plan. This is the single most common procedural mistake. If your doctor's office is unfamiliar with the Bridge, hand them the CMS Medicare GLP-1 Bridge page and the payer sheet. Part D plans receiving Bridge PAs will reject them — that rejection is not the Bridge denying you; it's just the wrong destination.
6
Fill your prescription on or after July 1, 2026
Pharmacies don't need to opt in, but they do need to process the claim using the correct Bridge payer-sheet routing (BIN 028918, PCN MEDDGLP1BR). You pay $50 at the counter.

Get my Doctor Visit Kit — one-page printable with your tier, CMS attestation language, documentation checklist, and PA routing instruction →

Free. No email required. Outputs a prescriber checklist with your tier and CMS attestation language.

What documents to bring + scripts your doctor and pharmacy will recognize

The Bridge is unusual: it doesn’t run through your Part D plan. Your prescriber’s office may not be familiar with the workflow, and your pharmacy may need a moment to look up the correct payer information. Bringing the right documents and using clear language at both stops removes the most common friction points.

Documents every applicant should gather

•Medicare card showing Part D or MA-PD coverage
•Current medication list (especially if you're already on a GLP-1)
•Height and weight history — current and at GLP-1 therapy initiation if applicable
•Pharmacy name, address, and NPI if you can pull it

Route-specific documentation

If you’re qualifying via	Useful records to bring
Tier 1 — BMI ≥ 35	Current weight and height, prior weight history if already on a GLP-1
Tier 2 — BMI ≥ 30 + HFpEF	Cardiology note, echocardiogram summary if available, diagnosis list
Tier 2 — BMI ≥ 30 + uncontrolled hypertension	Blood pressure logs (multiple readings), medication list showing two antihypertensives
Tier 2 — BMI ≥ 30 + CKD Stage 3a+	eGFR labs, nephrology or primary-care note documenting CKD stage
Tier 3 — BMI ≥ 27 + prediabetes	A1C lab result or fasting glucose record per ADA guidelines
Tier 3 — BMI ≥ 27 + prior MI / stroke	Hospital discharge summary, cardiology or neurology records
Tier 3 — BMI ≥ 27 + symptomatic PAD	Vascular surgery note, ABI test result, or cardiology workup

A short script for your prescriber

“I have Medicare Part D coverage and I think I may meet the CMS Medicare GLP-1 Bridge criteria for weight reduction. Could we review which BMI route I might fit, and if I’m eligible, can your office submit the prior authorization to the Bridge central processor — not my Part D plan — when the program opens July 1?”

A short script for your pharmacy

“This may be a Medicare GLP-1 Bridge claim, not a standard Part D claim. CMS has published a Bridge payer sheet — BIN 028918, PCN MEDDGLP1BR, processor SS&C Health, routed through RelayHealth, effective July 1, 2026. Help desk is 844-673-0910. Could you check the latest Medicare GLP-1 Bridge payer sheet?”

What BIN, PCN, and pharmacy details does the Medicare GLP-1 Bridge use?

CMS has published the Medicare GLP-1 Bridge payer sheet (dated March 16, 2026). The exact routing details:

Field	Value
Payer name	CMS Medicare Part D
Plan name	GLP1Bridge
BIN	028918
PCN	MEDDGLP1BR
Processor	SS&C Health
Claims routed through	RelayHealth
Effective date	July 1, 2026
Help desk	844-673-0910
Cardholder ID	The beneficiary's MBI (Medicare Beneficiary Identifier) as it appears on the Medicare card
Compounds	Not allowed
Paper claims	Not accepted
Direct member reimbursement	Not accepted

Source: CMS Medicare GLP-1 Bridge payer sheet, dated March 16, 2026.

How the prior authorization actually works

Quick answer: Your prescriber submits a prior authorization request and prescription to the CMS central processor (Humana, using its LI NET infrastructure, with claims processed through SS&C Health and routed via RelayHealth) — not to your Part D plan. The PA attests to your BMI/condition tier, weight-loss indication with lifestyle modification, and age ≥ 18.

Your Part D plan is not the gatekeeper for the Bridge. It doesn’t issue the PA, doesn’t pay the claim, and doesn’t bear any financial risk for it. Part D plan sponsors aren’t even required to opt into the Bridge for you to use it — CMS runs the program directly.

The most common procedural mistake

If your doctor’s office accidentally sends the PA to your Part D plan, you’ll likely get a denial. That denial is not the Bridge denying you — it’s just the wrong destination. CMS has asked plans to redirect such requests to the central processor, but if you receive a confusing denial letter, ask your doctor’s office to resubmit through the Bridge BIN/PCN.

Your prescriber does not need to be enrolled in Medicare to submit a Bridge PA, but cannot be on the CMS Preclusion List. The Bridge does not modify your existing Part D appeal rights. CMS’s public Bridge FAQ and payer sheet do not publish a separate consumer appeal pathway specifically for Bridge determinations.

When to use regular Part D instead of the Bridge

If your GLP-1 is prescribed for a use already coverable under regular Medicare Part D — type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea with obesity — your prescriber follows the Part D process, not the Bridge process.

Why is your GLP-1 being prescribed?	Path
Weight reduction and maintenance only	Bridge (if you meet the criteria)
Type 2 diabetes (Ozempic, Mounjaro, Rybelsus)	Regular Part D — coverage depends on plan formulary
Cardiovascular risk reduction in established CV disease + obesity/overweight (Wegovy)	Regular Part D — formulary exception if not on formulary
Moderate-to-severe OSA + obesity (Zepbound)	Regular Part D — formulary exception if not on formulary

The cleanest way to check Part D coverage

Use Medicare Plan Finder at medicare.gov/plan-compare (free, official, takes about 5 minutes with your drug list) or call 1-800-MEDICARE or your Part D plan directly. Don’t run Medicare coverage checks through commercial telehealth tools — most can’t coordinate government-plan coverage.

Don’t let the Bridge headlines distract you from a Part D path that may give you better cost-sharing — especially since regular Part D drug spending counts toward your $2,100 OOP cap and the Bridge does not.

Can a telehealth provider help with the Bridge?

Probably not for the Bridge itself. Most major telehealth GLP-1 services don’t currently coordinate coverage for government insurance plans like Medicare. The Bridge runs through your prescribing doctor and a CMS central processor — not through a telehealth platform.

For the Bridge, your best path is your established primary care doctor or another Medicare-accepting prescriber. If you don’t have one, schedule a new-patient visit now — that relationship is the pacing item for everything else.

Situation	Telehealth fit
You qualify for the Bridge	Use your PCP, not telehealth
You want to verify Part D coverage for an existing condition	Use Medicare Plan Finder or call your plan — not a commercial telehealth tool
You don't qualify for the Bridge and want FDA-approved cash-pay options	Some telehealth services offer Foundayo, Wegovy, and Zepbound at LillyDirect/NovoCare-matched cash prices
You want compounded GLP-1s	Separate decision, separate page — we don't recommend mixing compounded options into a Medicare-coverage discussion

What if you don’t qualify for the Bridge?

Most readers who don’t qualify fall into one of three buckets, each with a real path.

Path 1 — You have diabetes, OSA, or established cardiovascular disease

Your Part D plan may already cover a GLP-1 for the indication you have. Your cost-sharing is whatever your Part D plan charges (which may be more or less than $50 — but it counts toward your OOP cap).

Type 2 diabetes → Ozempic, Mounjaro, or Rybelsus are commonly on Part D formularies
Established CV disease + overweight/obesity → Wegovy is FDA-approved for cardiovascular risk reduction since March 2024
Moderate-to-severe OSA + obesity → Zepbound is FDA-approved for OSA

Pull your Part D formulary (on your plan’s website or call the plan), or use medicare.gov/plan-compare. If your drug isn’t on formulary for an FDA-approved indication you have, your doctor can request a formulary exception.

Path 2 — Your state Medicaid joins BALANCE

The BALANCE Model in Medicaid is rolling out on a state-by-state, voluntary basis from May 2026 through January 2027. Watch your state Medicaid agency’s pharmacy bulletin or the CMS BALANCE Model page monthly through 2026. Note: BALANCE in Medicare Part D is not launching in 2027 (announced April 21, 2026). The Medicaid side is still moving forward.

Path 3 — Cash-pay branded GLP-1 telehealth (for non-qualifiers and pre-July 2026 starters)

If you don’t qualify for the Bridge, want to start before July 1, 2026, or want a backup plan for post-2027 uncertainty, FDA-approved branded telehealth gives you the same medication via a different payment structure. Ro is the most relevant fit for this audience for cash-pay access.

Ro Body — FDA-approved cash-pay GLP-1 (for non-qualifiers and pre-July starters)

Carries Foundayo, Wegovy (injection and tablets), and Zepbound KwikPen at LillyDirect/NovoCare-matched pricing on the medication itself. Ro Body membership: $39 first month, then as low as $74/month with annual prepay (or $149/month ongoing). Membership covers the clinician relationship; medication billed separately.

Important: Ro is for cash-pay or commercial insurance. Ro publicly states it currently can’t coordinate GLP-1 coverage for government insurance plans like Medicare. If you want the $50 Bridge price, your path is your PCP and a Bridge prior authorization — not Ro. Ro is right for the non-qualifier and the pre-July starter.

See current Ro pricing for Foundayo, Wegovy, and Zepbound →

Disclosure: The RX Index may earn a commission. This does not affect the CMS eligibility criteria, plan-type matrix, or drug list on this page.

What changed in April 2026 (and why your end date is now December 31, 2027)

April 1 & 6, 2026

+FDA approved Foundayo (orforglipron) — April 1, 2026
+CMS added Foundayo to the eligible Bridge drug list — April 6, 2026
!CMS clarified Zepbound to KwikPen formulation only — single-dose vial and single-dose pen excluded

April 21, 2026

CMS sought voluntary participation from Part D plan sponsors for the BALANCE Model. Plan participation fell short — so BALANCE will not launch in Medicare Part D in 2027. Instead, the Bridge is extended through December 31, 2027 — eighteen months total, three times longer than originally scheduled. According to KFF analysis, even with the $245 manufacturer net price, plans concluded they couldn’t absorb the volume risk without higher Part D premiums for all enrollees.

What it means for your planning

Good news

18 months of $50/month access instead of 6 months. $900 over 18 months instead of $300 over 6 — much longer to make medical and lifestyle progress.

Less certain

What happens after December 31, 2027 is genuinely unknown. CMS has not announced the path forward. Don't plan finances assuming Bridge-rate access continues past 2027.

Practical advice

Use this 18 months to make medical progress, understand whether Part D covers a GLP-1 for any other indication you have, and build a budget contingency for 2028.

Bridge vs. BALANCE — quick comparison

Feature	Medicare GLP-1 Bridge	BALANCE Model (Medicare side)
Status	Active July 1, 2026 – December 31, 2027	Not launching in Medicare Part D in 2027
Payment flow	Outside Part D — CMS central processor	Would have integrated with participating Part D plans
Plan opt-in required?	No — Part D sponsors are not involved	Yes — voluntary plan participation
Cost-sharing	$50/month flat copay	Would have varied by plan type
OOP cap impact	Doesn't count	Would have counted
Reader action	Prescriber PA to central processor	Watch CMS for future guidance

Medical safety: what to ask your clinician about

Wegovy, Zepbound, and Foundayo each have FDA-approved labels with serious warnings, contraindications, and monitoring requirements. The Bridge is a coverage program. The medications carry real risks regardless of how they’re paid for.

Things to discuss with your clinician

•Boxed warning for thyroid C-cell tumors — contraindicated in people with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
•Pancreatitis and gallbladder disease — severe abdominal pain warrants prompt evaluation.
•Severe gastrointestinal reactions (nausea, vomiting, diarrhea, dehydration) — may require dose adjustment.
•Acute kidney injury due to volume depletion, especially during dose escalation or with persistent vomiting.
•Hypoglycemia risk if also taking insulin or insulin secretagogues (common for diabetic patients on combination therapy).
•Diabetic retinopathy in patients with type 2 diabetes — sudden glycemic improvement may transiently worsen retinopathy.
•Pregnancy and breastfeeding considerations.
•Pulmonary aspiration during anesthesia or deep sedation — let your surgical team know you're on a GLP-1 well in advance of any procedure.

Sources: FDA prescribing labels for Wegovy, Zepbound, and Foundayo. The Bridge eligibility criteria and FDA prescribing label are two completely different gates — clearing one doesn’t clear the other.

Pharmacy and plan troubleshooting (when things go sideways)

Because the Bridge runs outside normal Part D plumbing, expect some early confusion — especially in July and August 2026. Most issues come down to four things.

Your Part D plan denied the prior authorization

The PA was probably sent to the wrong place. The Bridge PA goes to the CMS central processor (Humana / LI NET, with claims processed through SS&C Health and routed via RelayHealth) — not to your Part D plan. Have your doctor's office resubmit through the Bridge BIN/PCN.

The pharmacy can't find the claim path

Hand them the payer sheet details: BIN 028918, PCN MEDDGLP1BR, processor SS&C Health, RelayHealth routing, effective July 1, 2026. Help desk: 844-673-0910. CMS says pharmacies don't need to opt in, but they do need to process the electronic Bridge claim using the correct payer-sheet information.

The prescription is for the wrong Zepbound formulation

The Bridge covers Zepbound KwikPen only. If your prescription was written for the Zepbound vial or single-dose pen, ask your prescriber to rewrite it specifying the KwikPen.

The attestation language is missing or wrong

The PA must attest that the prescription is for weight reduction and maintenance, and that you're being treated alongside structured nutrition and physical activity per the FDA label. If your doctor's office is unfamiliar with the exact wording, the Doctor Visit Kit linked above includes the verbatim CMS language.

When to escalate

If you’ve documented a clean PA submission to the central processor and you’re still getting denied without a substantive reason, contact 1-800-MEDICARE and request an explanation. For now, calm troubleshooting beats angry escalation — the program is brand new, and guidance is still being finalized.

Print the pharmacy desk card before your first fill — includes BIN, PCN, processor, help desk, and the 'compounds not allowed' reminder →

Free. No email required. Outputs a prescriber checklist with your tier and CMS attestation language.

What we verified — and what’s still pending

Verified directly against CMS as of April 25, 2026

✅The Bridge runs July 1, 2026 through December 31, 2027 (extended April 21, 2026)

✅Available nationwide, all states and territories

✅Eligible plan types: standalone PDP, MA-PD coordinated care plans, SNPs, EGWPs, LI NET, and dually eligible beneficiaries in eligible plan types

✅Three clinical eligibility tiers with the BMI and condition criteria as published

✅Eligible drugs: Wegovy® (injection and tablets, all CMS-listed formulations), Zepbound® KwikPen, Foundayo® (added April 6, 2026)

✅$50 monthly copay; $245 manufacturer net price

✅Operates outside Part D — does not count toward deductible or $2,100 OOP cap

✅LIS subsidies do not apply

✅Manufacturer coupons cannot be applied

✅Provider Medicare-enrollment not required, but provider must not be on Preclusion List

✅Pharmacies do not need to opt in

✅Central processor is Humana, using LI NET infrastructure

✅Pharmacy claims routing — BIN 028918, PCN MEDDGLP1BR, processor SS&C Health, routed through RelayHealth, effective July 1, 2026

✅Compounds not allowed (per CMS payer sheet)

✅Help desk: 844-673-0910

Still pending or to be re-verified

⚠Standardized PA messaging between Part D plans and the central processor (CMS working with NCPDP on the messaging guide)

⚠Whether specific telehealth providers will support Bridge PAs — most haven't published Medicare-specific PA workflows yet

⚠NDC list updates — CMS may update which formulations are covered as new approvals occur

⚠Post-December 31, 2027 path — uncertain; we update this page when CMS publishes new guidance

Primary sources: CMS Medicare GLP-1 Bridge FAQ · CMS Bridge payer sheet (3/16/2026) · CMS BALANCE Model page · KFF analysis

Frequently Asked Questions

Is the Medicare GLP-1 Bridge program real?

Yes. It's a CMS-run demonstration authorized under Section 402 of the Social Security Amendments of 1967, announced December 23, 2025. It launches July 1, 2026 and runs through December 31, 2027.

When does the Medicare GLP-1 Bridge start?

July 1, 2026.

When does the Medicare GLP-1 Bridge end?

December 31, 2027 — extended on April 21, 2026 from the original December 31, 2026 end date.

Who qualifies for the Medicare GLP-1 Bridge?

Medicare beneficiaries who are 18+, enrolled in an eligible Part D plan type, and meet one of three BMI/condition tiers: BMI ≥ 35 alone, BMI ≥ 30 plus HFpEF/uncontrolled hypertension on 2 meds/CKD Stage 3a+, or BMI ≥ 27 plus prediabetes/prior MI/prior stroke/symptomatic PAD.

Does BMI ≥ 30 alone qualify?

No. BMI ≥ 30 qualifies only with one of three specific conditions: HFpEF, uncontrolled hypertension treated with two antihypertensive medications, or CKD Stage 3a or higher. BMI ≥ 35 alone qualifies; BMI ≥ 30 alone does not.

Does prediabetes qualify for the Medicare GLP-1 Bridge?

Yes — if your BMI is ≥ 27 at therapy initiation. Prediabetes alone does not qualify; the BMI threshold must also be met.

Does sleep apnea qualify for the Bridge?

No. Sleep apnea is not a Bridge-qualifying condition. However, Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity — that prescription goes through your regular Part D plan, not the Bridge.

Does Wegovy qualify for the Medicare Bridge?

Yes — when prescribed for weight reduction and maintenance and you meet the eligibility criteria. Wegovy injection and tablets are both included.

Does Zepbound qualify for the Medicare Bridge?

Only the KwikPen formulation. The single-dose vial and single-dose pen are not Bridge-eligible.

Does Foundayo qualify for the Medicare Bridge?

Yes. Foundayo (orforglipron) was FDA-approved April 1, 2026 and added to the CMS Bridge eligible list April 6, 2026. Wegovy tablets are also Bridge-eligible if you want an oral option.

Does Ozempic qualify for the Medicare Bridge?

No — Ozempic is not Bridge-covered. Many Part D plans cover Ozempic for type 2 diabetes through your regular Part D benefit, subject to plan formulary and utilization rules.

Do compounded GLP-1s qualify for the Bridge?

No. The Bridge covers FDA-approved medications only. The CMS payer sheet specifies 'compounds not allowed.'

Does the $50 copay count toward my Part D out-of-pocket cap?

No. The Bridge operates outside Part D, so the $50 doesn't count toward the $2,100 OOP cap or your deductible.

Does Extra Help (LIS) reduce the $50 copay?

No. Low-Income Subsidy cost-sharing does not apply to Bridge claims. You pay the full $50 even if you're on Extra Help.

Can I use a manufacturer coupon with the Bridge?

No. Coupons and discount programs cannot be applied to Bridge claims.

Who submits the prior authorization for the Medicare Bridge?

Your prescriber. The PA goes to the CMS central processor (Humana / LI NET, with claims routed through SS&C Health and RelayHealth) — not to your Part D plan.

Does my doctor have to be enrolled in Medicare to write a Bridge prescription?

No. CMS does not require Medicare enrollment for the prescriber. However, the prescriber must not be on the CMS Preclusion List.

What if I already started a GLP-1 before July 2026?

You may still qualify. CMS specifically allows you to qualify based on the BMI you had when you started GLP-1 therapy — even if your current BMI is now lower because the medication is working.

What if my pharmacy doesn't know how to process the Bridge claim?

Give them the payer sheet details: BIN 028918, PCN MEDDGLP1BR, processor SS&C Health, RelayHealth routing, help desk 844-673-0910. CMS says pharmacies do not need to opt in, but they do need to process the electronic Bridge claim using the correct payer-sheet information.

Can a telehealth provider handle the Medicare Bridge prior authorization?

Most don't currently coordinate GLP-1 coverage for government insurance plans. Your established primary care doctor or another Medicare-accepting prescriber is the right path for Bridge prior authorizations. Telehealth is the right path for cash-pay or commercial-insurance access — not for the Bridge.

Still not sure which Medicare GLP-1 path is right for you?

Take our free 60-second matching quiz. Answer five questions about your Medicare plan, your conditions, and your goals — get a personalized action plan covering the Bridge, regular Part D, Medicaid BALANCE (if applicable in your state), and FDA-approved cash-pay alternatives. No email required.

Take the 60-second Medicare GLP-1 match quiz →

Free. No email required. Personalized action plan for Bridge, Part D, BALANCE, and cash-pay.

Related guides

Author: The RX Index Editorial Team. We are not your medical or financial advisors — every clinical decision belongs with your prescriber, every coverage decision involves your specific plan. Last verified: April 25, 2026. Next scheduled re-verification: May 25, 2026 (monthly cadence through 2026 due to high regulatory velocity). Disclosure: The RX Index may earn a commission when readers use certain provider links in this article (specifically Ro). This does not influence the eligibility criteria, plan-type matrix, drug list, central-processor routing instructions, or alternative-paths guidance — those are built directly from CMS source material.